Trial Condition(s):

Macular degeneration

Study to assess the EffectiVeness of exIsting anti-vascular Endothelial groWth factor (anti-VEGF) treatment regimens in patients with wet age-related macular degeneration (REVIEW)

Bayer Identifier:

16378

ClinicalTrials.gov Identifier:

NCT01933152

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until December 31, 2011. Switch to any other Anti vascular endothelial growth factor (anti VEGF) treatment will be documented. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.

Inclusion Criteria
- Diagnosis of wet Age-related Macular Degeneration
- Start of anti-VEGF therapy with ranibizumab (Lucentis) between January 1, 2009 and December 31, 2009
- Informed consent form signed
Exclusion Criteria
- Participation in an investigational study during anti-VEGF therapy (from start up to December 31, 2011) that involved treatment with any drug or device

Trial Summary

Enrollment Goal
137
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
No Drug
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Portugal

Status
Completed
 

Trial Design